Important News & Announcements

Stay up to date with the latest news and announcements from NASCSA.

Back to all news

Webinar of Interest to Members - The End of the COVID-19 Emergency: The Ryan Haight Act, Telemedicine, and Next Steps on Thursday, March 23, 2023 at 12 Noon EST

Posted 3/13/2023

The COVID-19 pandemic emergency forced federal regulators to take extraordinary measures to ensure that patients were permitted continued access to important medicines. These government measures included granting temporary exemptions from certain FDA and DEA legal requirements. When the public health emergency ends on May 11, 2023, so do these exemptions. By almost all accounts, these exemptions also improved prescribing and dispensing of medication to patients that need them. The ?end? of the pandemic emergency leaves many in the regulated industry wondering how this will affect certain prescribing and dispensing practices that have become ubiquitous since the pandemic?s inception.

Hyman, Phelps & McNamara, P.C.?s panel of legal experts (Karla Palmer, John Claud, Jeff Wasserstein, John Gilbert and Kalie Richardson) invite you to spend your lunch hour (or hour-and-a-half?) with us as we address implications related to the looming end of the pandemic declaration. We will discuss the state of relevant laws prior to our new ?COVID reality? and telemedicine issues during and post-pandemic, both with respect to the prescribing of controlled substances and non-controlled drugs. Last, but certainly not least, we look forward to introducing our newest colleague, John WM Claud, who recently joined HPM from the Department of Justice?s Consumer Protection Branch. John will present on considerations and his learned perspective for the future of teleprescribing.

Please see detailed information in the attached flyer, including a link to register for our free webinar. We hope you join us!

Back to all news

Sponsor Spotlight

COMPASS Pathways


COMPASS Pathways is delighted to be a sponsor of NASCSA and looks forward to both engaging with controlled substances authorities, NASCSA leadership, and members to learn about their important work, and educate about our company's mission and the innovations underway using novel therapies.

COMPASS Pathways is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments.

We are developing innovative therapies and, when appropriate, combining them with psychological support and next-generation digital tools to forge new, sustainable mental health care pathways.

Our investigational COMP360 psilocybin therapy is currently undergoing phase 3 investigation in treatment-resistant depression. We are also assessing COMP360 in anorexia nervosa and post-traumatic stress disorder, across multiple clinical studies.

Learn more https://www.compasspathways.com

All Sponsors